logo-loader

OptiBiotix inks licence agreement for LPLDL compound in Italy

Published: 07:35 21 Jun 2018 BST

Handshake
The group added that the agreement would include an upfront payment and royalties

OptiBiotix Health plc (LON:OPTI) has signed a licence agreement to commercialise food supplements containing its LPLDL strain in the Italian market.

The AIM-listed life sciences company, which develops compounds to tackle obesity, high cholesterol, diabetes and skin care, said the 10-year agreement would grant ALFASIGMA, a multinational pharmaceutical company, a licence to promote food supplements containing the LPLDL strain for cardiovascular health, throughout Italy. 

READ: First supplement containing OptiBiotix’s breakthrough cholesterol-lowering strain launched in U

The group added that the agreement would include an upfront payment and royalties with five-figure guaranteed minimum payments.

Italy is the largest probiotic supplement market in Europe and the second largest market in the world with a value of over US$500mln and a 25% per annum growth forecast to 2021.

Per Rehne, commercial director of OptiBiotix, said: “This agreement is another deal from a very strong pipeline with industry partners of increasing size and revenue potential targeted at the largest and fastest growing markets around the world."

The agreement follows the launch of OptiBiotix’s LPLDL strain in the US market after the company struck a deal with US supplement maker, Seed Health, in May.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

3 hours, 7 minutes ago